NEW YORK (
said Tuesday it discontinued development of motavizumab for preventing serious respiratory syncytial virus disease and will record a fourth-quarter impairment charge of $445 million.
AstraZeneca said the charge won't impact its 2010 earnings guidance.
The company said it requested the withdrawal of the biological license application for the drug that was pending at the U.S. Food and Drug Administration. It filed the BLA in January 2008.
The FDA has asked for more clinical data on the drug in August.
AstraZeneca said motavizumab remains in development for other respiratory syncytial virus treatments.
RSV causes more than 125,000 infant hospitalizations each year, and up to 500 deaths, according to studies cited by AstraZeneca, the
-- Written by Joseph Woelfel
>To contact the writer of this article, click here:
>To submit a news tip, send an email to: